Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.
Abstract
We evaluated the safety and efficacy of an optimized adeno-associated virus (AAV; AAV2.RPE65) in animal models of the RPE65 form of Leber congenital amaurosis (LCA). Protein expression was optimized by addition of a modified Kozak sequence at the translational start site of hRPE65. Modifications in AAV production and delivery included use of a long stuffer sequence to prevent reverse packaging from the AAV inverted-terminal repeats, and co-injection with a surfactant. The latter allows consistent and predictable delivery of a given dose of vector. We observed improved electroretinograms (ERGs) and visual acuity in Rpe65 mutant mice. This has not been reported previously using AAV2 vectors. Subretinal delivery of 8.25 x 10(10) vector genomes in affected dogs was well tolerated both locally and systemically, and treated animals showed improved visual behavior and pupillary responses, and reduced nystagmus within 2 weeks of injection. ERG responses confirmed the reversal of visual deficit. Immunohistochemistry confirmed transduction of retinal pigment epithelium cells and there was minimal toxicity to the retina as judged by histopathologic analysis. The data demonstrate that AAV2.RPE65 delivers the RPE65 transgene efficiently and quickly to the appropriate target cells in vivo in animal models. This vector holds great promise for treatment of LCA due to RPE65 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jean Bennett's group enhanced safety and maximized the therapeutic effect by adding a stuffer sequence for rAAV product hRPE65v2 [39,226].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [226]
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationDOUGLAS, R. M., ALAM, N. M., SILVER, B. D., MCGILL, T. J., TSCHETTER, W. W., & PRUSKY, G. T. (2005) · Visual Neuroscience · doi:10.1017/s0952523805225166 · Cited by 405
Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., Dollfus, H., Hamel, C., Lopponen, T., et al. (2004) · Human Mutation · doi:10.1002/humu.20010 · Cited by 350
Lyubarsky, A. L., Falsini, B., Pennesi, M. E., Valentini, P., & Pugh, E. N. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-01-00442.1999 · Cited by 273
Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Aguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationPang, J., Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Li, J., Noorwez, S. M., Malhotra, R., McDowell, J. H., Kaushal, S., et al. (2005) · PubMed · Cited by 227
Recovery phase of the murine rod photoresponse reconstructed from electroretinographic recordings
Lyubarsky, A., & Pugh, E. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-02-00563.1996 · Cited by 225
Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction.
Bennett, J., Duan, D., Engelhardt, J. F., & Maguire, A. M. (1997) · PubMed · Cited by 204
Self-citation
Cited by
Items 201–268 of 268
Intravitreal Injection of AAV for the Transduction of Mouse Retinal Ganglion Cells
Nieuwenhuis, B., & Osborne, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3409-7_17 · Cited by 7
Bennett, J. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2529 · Cited by 4
“…work on this trial through generating a clinical vector, building a full set of safety and efficacy data, breeding animals for study, designing clinical protocols and outcome measures, purchasing the necessary equipment, and enrolling the first subject in a short 2.3 years (Bennicelli et al. , 2008).”
InfluentialSelf-citationPromising First Steps in Gene Therapy for Choroideremia
Huckfeldt, R. M., & Bennett, J. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2503 · Cited by 4
“…et al., 2003; Tolmachova et al., 2012, 2013; Vasireddy et al., 2013); (6) conditions whereby accurate dosing of AAV is assured had been developed (Bennicelli et al., 2008); and (7) the safety of subretinal and subfoveal injection of AAV serotype 2 (AAV2) and incorporation of the chicken beta…”
Self-citationHow could gene therapy change the way we treat age-related macular degeneration?
Khan, H., Khan, H., Aziz, A. A., Ewing, T., & Khanani, A. M. (2022) · Expert Review of Ophthalmology · doi:10.1080/17469899.2022.2147927 · Cited by 3
Polysorbates and poloxamer rescue filter-induced serotype-dependent loss of AAVs
Patrick, C., Petroff, M., Plegaria, J. S., Razinkov, V. I., Padmakumar, S., & Mallela, K. M. G. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103825 · Cited by 4
Hassan, S., Hsu, Y., Mayer, S. K., Thomas, J., Kothapalli, A. J., Helms, M., Baker, S. A., Laird, J. G., Bhattarai, S., & Drack, A. V. (2023) · Saudi Journal of Ophthalmology · doi:10.4103/sjopt.sjopt_155_23 · Cited by 3
“[1,2] ] However, in mice as in humans, the ERG becomes nonrecordable before all vision is lost, [6,7] making subtle treatment effects impossible to measure.”
BackgroundMethodIntravitreal AAV2 gene delivery to feline retinal ganglion cells
Oikawa, K., Eaton, J. S., Kiland, J. A., Torné, O., Mathu, V., Nickells, R. W., & McLellan, G. J. (2024) · Vision Research · doi:10.1016/j.visres.2024.108519 · Cited by 3
“Pre-clinical studies in dogs bearing an RPE65 gene mutation supported human clinical trials that resulted in the first FDA approved ocular gene therapy (Acland et al., 2001; Beltran et al., 2012; Bennicelli et al., 2008; Petersen-Jones et al., 2012).”
Wei, S. C., Cantor, A. J., Walleshauser, J., Mepani, R. J., Melton, K., Bans, A., Khekare, P., Gupta, S., Wang, J., Soares, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317387 · Cited by 3
“For example, large animal models have been previously utilized for the evaluation and development of AAV-based gene therapy for Leber Congenital Amaurosis (LCA) [39–41].”
Safety of Adeno-Associated Viral Vectors
Lin, S., & Ertl, H. C. J. (2008) · Future Virology · doi:10.2217/17460794.3.5.491 · Cited by 3
“The procedure did not cause toxicity as judged by histopathological analysis [106].”
MethodImplants for artificial vision
Walter, P. (2009) · Expert Review of Ophthalmology · doi:10.1586/eop.09.42 · Cited by 3
Gene Therapy for Diabetic Retinopathy in Animal Models and Humans
Mizukami, H. (2011) · The Open Diabetes Journal · doi:10.2174/1876524601104010119 · Cited by 3
“Subsequently, human clinical trials have been carried out and successful results have recently been reported [6].”
BackgroundSuccess of Gene Therapy in Late-Stage Treatment
Koch, S., & Tsang, S. H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_13 · Cited by 3
Thurtell, M. J., & Tomsak, R. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00046-3 · Cited by 3
Subretinal Injection Volume Correlates to Persistent Outer Retinal Thinning in the Pig Eye
Seitz, I. P., Nyshchuk, R., Ellederová, Z., Ardan, T., Juhásová, J., Nemesh, Y., Juhás, Š., Drutovič, S., Süßkind, D., Schnichels, S., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.14.27 · Cited by 3
“Looking at the history of VN tolerability through the lens of SRV, it is noteworthy that the preclinical VN studies in RPE65 − / − Briard dogs 40,41 and NHPs 42 in which no retinal thinning and atrophy were reported used smaller SRVs of 100-200 μL, compared to a larger SRV of 300 μL in human…”
Liu, X., & Zhang, Y. (2016) · Hereditary Genetics · doi:10.4172/2161-1041.1000163 · Cited by 2
“With this knowledge, progress of gene-replacement therapies for several inherited retinal diseases has been made through pre-clinical and clinical studies in recent years [5-10].”
BackgroundGene Therapy for Retinal Disease
Bennett, J., & Maguire, A. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00034-5 · Cited by 2
Self-citationAravand, P., Ramachandran, P. S., Shpylchak, I., Phelps, N. T., Nikonov, S. S., & Bennett, J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00215 · Cited by 2
“hRPE65v2 (Bennicelli et al., 2008), a recombinant AAV that delivers the wildtype hRPE65 cDNA driven by a constitutive (chicken β actin promoter with CMV enhancer) (Amado et al.”
BackgroundMethodSelf-citationLiatis, T., & Cherubini, G. B. (2020) · Topics in companion animal medicine · doi:10.1016/j.tcam.2020.100439 · Cited by 1
Reichel, F. F., Király, P., Seitz, I. P., & Fischer, M. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073705 · Cited by 1
“Previous studies have shown significant differences in the recovery rates from AAV-based gene therapeutic products between application devices [11–13 The application of precise and consistent doses of AAV is, however, critical to ensure the efficacy of the treat-ment, while limiting off-target…”
BackgroundMethodInfluentialRetinal Degenerations: Genetics, Mechanisms, and Therapies
MacDonald, I. M., Naash, M. I., & Ayyagari, R. (2011) · Journal of Ophthalmology · doi:10.1155/2011/764873 · Cited by 1
Recent Developments in Maculopathy
Bandello, F. M., Battista, M., Brambati, M., Starace, V., Arrigo, A., & Parodi, M. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-25389-9_6 · Cited by 1
Gene Therapy, Diet and Drug Approaches to Treating Inherited Retinal Disease
Simunovic, M. P., Mack, H. G., Ayton, L. N., & Hassall, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00154-7 · Cited by 3
Cardiac Gene Delivery in Large Animal Models: Antegrade Techniques
Mavropoulos, S. A., Yamada, K. P., Sakata, T., & Ishikawa, K. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2707-5_11 · Cited by 1
Neroev, V. V., Катаргина, Л. А., Kharlampidi, M. P., Коголева, Л. В., Zolnikova, I. V., Ilyukhin, P. A., Denisova, E. V., Викторович, М. С., Осипова, Н. А., Kutsev, S. I., et al. (2023) · Russian Ophthalmological Journal · doi:10.21516/2072-0076-2023-16-4-50-62 · Cited by 1
Neitz, M., & Neitz, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-815234-8.00012-4 · Cited by 2
Recent advances on modeling retinal disease: Towards efficient gene/drug therapy
Dolatabadi, E. N., Zaky, M. R. A., Abbas, F. H., Milani, A. E., André, H., & Alizadeh, E. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110416 · Cited by 1
Gene Therapy for Choroideremia
Barnard, A. R., Groppe, M., & MacLaren, R. E. (2014) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-662-45188-5_3 · Cited by 3
Hassall, M., & Simunovic, M. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-7644-7_35 · Cited by 1
Hellström, M. (2010) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 1
Askou, A. L., & Corydon, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2389-2_3
Em busca de novos métodos de tratamento para a retinose pigmentar causada por mutações na rodopsina.
Balen, F. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2012.tde-13112012-092432
Gene Therapy for Leber’s Congenital Amaurosis Due to RPE65 Mutations
Bennett, J. (2014) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-662-45188-5_2 · Cited by 1
Self-citationGrabska‐Liberek, I., Wasyluk, J., Derlacka, D., & Kowalska-Bylak, K. (2013)
EUROPEAN SCHOOL OF MOLECULAR MEDICINE
Napoli, S. D. (2010)
Maguire, A. M. (2008)
Self-citationDog Models for Blinding Inherited Retinal Degenerations
Petersen‐Jones, S. M., & Komáromy, A. M. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/hum.2014.155
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.003
[Treatment of nicotine-induced circulatory diseases of the legs].
Kuhlmann, F. (1980) · PubMed
Disorders of the visual system
Thompson, S., & Philp, A. R. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.004
Breakthroughs and barriers in clinical gene therapy
Liang, K. J., Gaylor, J. P., & Samulski, R. J. (2015) · doi:10.4155/fseb2013.14.40
Sobre la terapia génica para enfermedades de la retina
Fischer, M. D. (2017) · Ophthalmologica · doi:10.1159/000477516 · Cited by 2
RNA interference therapy for the Spinocerebellar ataxias
Ramachandran, P. S. (2014) · doi:10.17077/etd.xa5w8n22
“AAV2, AAV5 and AAV8 have successfully been used for gene delivery to the retina in animal models of various retinal diseases (114-118) and in human patients with Lebers congenital amaurosis (LCA) (119).”
MethodTherapy and mechanism of Mendelian eye diseases
Tsai, Y.-T. (2018) · Columbia Academic Commons (Columbia University) · doi:10.7916/d8k37bhv
AAV-Nrf2 Mediated Rescue of Oxidative Stress in Mouse Models
Liang, K. J. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tmc2-r921
An Update on Ocular Gene Therapy for Monogenic and Multifactorial Retinal Diseases
Hou, A. Y., & Kiss, S. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419876750
“In late 2007, the team sponsored by Spark Therapeutics began its own phase 1 study (NCT00516477) looking at the safety and tolerability of subretinal AAV2-hRPE65v2, which used a CbA promoter with an optimized Kozak sequence.(33) They recruited 12 participants with RPE65-associated LCA and injected them, beginning with…”
Rescue of inherited retinal degeneration associated with Aipl1 defects
Ku, C. A. (2012) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4880
Moodle:データベース構築の実際(2)「小テスト」と「オンラインテキスト」について
表, 正. (2010) · 鹿児島国際大学情報処理センター研究年報
(2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32833079c5
High, K. A. (2023) · PubMed Central · Cited by 2
Self-citationTherapeutic strategies based on genetic interventions
Baek, R. C., Finn, P. F., & Martini, P. G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00013-6
Gene Therapy Trial on X-Linked Retinitis Pigmentosa Caused by Mutations in RPGR
de la Cámara, C. M.-F., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_17 · Cited by 1
Gene Therapy for Inherited Ocular Disorders
Tuszynski, M. H., & Rosenzweig, E. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_8
Genetic Counseling for Inherited Eye Disorders
Sutherland, J. E., Haseley, A., & DeBenedictis, M. J. (2025) · doi:10.1093/med/9780197659403.003.0002
Neitz, M., & Neitz, J. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0036
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737148
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737133
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737136
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737139
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737145
Sodi, A., Banfi, S., Testa, F., della Corte, M., Passerini, I., Pelo, E., Rossi, S., & Simonelli, F. (2021) · Figshare · doi:10.6084/m9.figshare.14737142
Thomas, S. P., Spinelli, M. M., Rghei, A. D., Lopes, J. A., Zielinska, N., McLeod, B. M., Pei, Y., Zhang, W., Thébaud, B., Karimi, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25698182
Singh, V., Huda, S., Kumar, G. N., & Jayandharan, G. R. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05485-2
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Varin, J. (2020) · theses.fr (ABES) · doi:10.70675/f838cd61z108az4e28z9344z0b8ab2eae6bf · Cited by 2
Okuda, T., Sugiura, M., Hirose, H., & Okamoto, H. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127007
Gogoleva, N., Tran, T.-H., Mayuko, O. K. I., Fukuda, S., Shahri, Z. J., Kumaga, E., Takahashi, S., & Hamada, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.21.739700
“Earlier voretigene development work showed that addition of 0.001% PF68 restored near-complete AAV2-RPE65 vector-genome recovery after passage through administration devices 26 .”
Influential
Metadata
- Authors
- Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., Wei, Z., Qu, G., Zhou, S., Zeiss, C., Arruda, V. R., Acland, G. M., Dell'Osso, L. F., High, K. A., Maguire, A. M., & Bennett, J.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Case Western Reserve University (US)
- Yale University (US)
- Cornell University (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 16
- Issue
- 3
- Pages
- 458-465
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC2842085
- OpenAlex
- W2035101755
- Cited by
- 267
- References
- 25
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 16 · 2023: 13 · 2022: 14 · 2021: 15 · 2020: 17 · 2019: 13 · 2018: 10 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 18 · 2013: 11 · 2012: 16
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3142 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- F. M. Kirby Foundation
- Research to Prevent Blindness
- Macula Vision Research Foundation
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY015398, R01EY006855, K12EY015398)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Leber congenital amaurosis, RPE65, AAV2, gene therapy, adeno-associated virus vectors, subretinal injection, retinal pigment epithelium, vector safety, electroretinogram, visual acuity, nystagmus, canine model, vector production
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Dogs, Electroretinography, Eye Proteins, Genetic Vectors, Immunohistochemistry, Mice, Knockout, cis-trans-Isomerases, Optic Atrophy, Hereditary, Leber, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.